BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 17673618)

  • 1. Tremelimumab (CP-675,206), a cytotoxic T lymphocyte associated antigen 4 blocking monoclonal antibody in clinical development for patients with cancer.
    Ribas A; Hanson DC; Noe DA; Millham R; Guyot DJ; Bernstein SH; Canniff PC; Sharma A; Gomez-Navarro J
    Oncologist; 2007 Jul; 12(7):873-83. PubMed ID: 17673618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with tremelimumab (CP-675,206).
    Ribas A
    Oncologist; 2008; 13 Suppl 4():10-5. PubMed ID: 19001146
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical development of the anti-CTLA-4 antibody tremelimumab.
    Ribas A
    Semin Oncol; 2010 Oct; 37(5):450-4. PubMed ID: 21074059
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ctla-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab?
    Ménard C; Ghiringhelli F; Roux S; Chaput N; Mateus C; Grohmann U; Caillat-Zucman S; Zitvogel L; Robert C
    Clin Cancer Res; 2008 Aug; 14(16):5242-9. PubMed ID: 18698043
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma.
    Kähler KC; Hauschild A
    J Dtsch Dermatol Ges; 2011 Apr; 9(4):277-86. PubMed ID: 21083648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tremelimumab: a review of development to date in solid tumors.
    Tarhini AA
    Immunotherapy; 2013 Mar; 5(3):215-29. PubMed ID: 23444951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II study.
    Maker AV; Phan GQ; Attia P; Yang JC; Sherry RM; Topalian SL; Kammula US; Royal RE; Haworth LR; Levy C; Kleiner D; Mavroukakis SA; Yellin M; Rosenberg SA
    Ann Surg Oncol; 2005 Dec; 12(12):1005-16. PubMed ID: 16283570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of lymphocyte regulation for cancer therapy: a phase II trial of tremelimumab in advanced gastric and esophageal adenocarcinoma.
    Ralph C; Elkord E; Burt DJ; O'Dwyer JF; Austin EB; Stern PL; Hawkins RE; Thistlethwaite FC
    Clin Cancer Res; 2010 Mar; 16(5):1662-72. PubMed ID: 20179239
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Overcoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010).
    Weber J
    Oncologist; 2008; 13 Suppl 4():16-25. PubMed ID: 19001147
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tremelimumab, a fully human monoclonal IgG2 antibody against CTLA4 for the potential treatment of cancer.
    Tarhini AA; Kirkwood JM
    Curr Opin Mol Ther; 2007 Oct; 9(5):505-14. PubMed ID: 17932815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of the CTLA4 blockade in the treatment of malignant melanoma.
    Cranmer LD; Hersh E
    Cancer Invest; 2007 Oct; 25(7):613-31. PubMed ID: 18027152
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CTLA-4 blockade with monoclonal antibodies in patients with metastatic cancer: surgical issues.
    Phan GQ; Weber JS; Sondak VK
    Ann Surg Oncol; 2008 Nov; 15(11):3014-21. PubMed ID: 18716842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel immunotherapies as potential therapeutic partners for traditional or targeted agents: cytotoxic T-lymphocyte antigen-4 blockade in advanced melanoma.
    Agarwala SS
    Melanoma Res; 2010 Feb; 20(1):1-10. PubMed ID: 19952852
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management.
    Kaehler KC; Piel S; Livingstone E; Schilling B; Hauschild A; Schadendorf D
    Semin Oncol; 2010 Oct; 37(5):485-98. PubMed ID: 21074064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint proteins: a new therapeutic paradigm for cancer--preclinical background: CTLA-4 and PD-1 blockade.
    Weber J
    Semin Oncol; 2010 Oct; 37(5):430-9. PubMed ID: 21074057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel therapies targeting the immune system: CTLA4 blockade with tremelimumab (CP-675,206), a fully human monoclonal antibody.
    Camacho LH
    Expert Opin Investig Drugs; 2008 Mar; 17(3):371-85. PubMed ID: 18321236
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer.
    Chung KY; Gore I; Fong L; Venook A; Beck SB; Dorazio P; Criscitiello PJ; Healey DI; Huang B; Gomez-Navarro J; Saltz LB
    J Clin Oncol; 2010 Jul; 28(21):3485-90. PubMed ID: 20498386
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206.
    Ribas A; Camacho LH; Lopez-Berestein G; Pavlov D; Bulanhagui CA; Millham R; Comin-Anduix B; Reuben JM; Seja E; Parker CA; Sharma A; Glaspy JA; Gomez-Navarro J
    J Clin Oncol; 2005 Dec; 23(35):8968-77. PubMed ID: 16204013
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies.
    O'Day SJ; Hamid O; Urba WJ
    Cancer; 2007 Dec; 110(12):2614-27. PubMed ID: 18000991
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma.
    Kirkwood JM; Lorigan P; Hersey P; Hauschild A; Robert C; McDermott D; Marshall MA; Gomez-Navarro J; Liang JQ; Bulanhagui CA
    Clin Cancer Res; 2010 Feb; 16(3):1042-8. PubMed ID: 20086001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.